UGN-102, a Direct-to-Bladder Therapy, Improves Bladder Cancer Outcomes

Findings from the phase 3 ATLAS and ENVISION trials reveal a non-surgical way to possibly benefit patients with low-grade, intermediate- risk non-muscle invasive bladder cancer.

Related Keywords

New Jersey ,United States ,Urogen Pharma ,Sandip Prasad ,Liz Barrett ,Drug Administration ,Genitourinary Surgical Oncology ,Morristown Medical ,Atlantic Health System ,New Drug Application ,